论文部分内容阅读
目的观察异基因造血干细胞移植(allo蛳HSCT)中出血性膀胱炎(HC)的发病情况,探讨其发病原因及防治效果。方法对allo蛳HSCT中12例次HC的危险因素和临床疗效进行分析。结果12例次HC患者中,早期HC2例次,迟发性HC10例次。8例出现病毒感染;10例出现急性移植物抗宿主病(GVHD),1例出现慢性GVHD。3例患者死亡,8例治愈。结论HC的发生除受环磷酰胺、白消安、TBI等的损害外,还与GVHD及病毒感染有关。在常规水化、碱化的基础之上加用美司那可降低早期HC的发生。HC的治疗除水化、碱化及利尿外,加用前列腺素E1和抗病毒治疗有效。
Objective To observe the incidence of hemorrhagic cystitis (HC) in allogeneic hematopoietic stem cell transplantation (HSC) and to explore its etiology and prevention and treatment. Methods Allo-HSCT in 12 cases of HC risk factors and clinical efficacy analysis. Results Among 12 cases of HC patients, the incidence of early HC2 was twice that of delayed HC10. 8 cases of viral infection; 10 cases of acute graft-versus-host disease (GVHD), 1 case of chronic GVHD. Three patients died and eight were cured. Conclusion The occurrence of HC in addition to cyclophosphamide, busulfan, TBI and other damage, but also with the GVHD and viral infection. On the basis of conventional hydration, basal application of metronidazole can reduce the incidence of early HC. HC treatment in addition to hydration, alkalization and diuresis, plus prostaglandin E1 and antiviral therapy.